CGS 21680 is a specific adenosine (A2A) subtype receptor agonist with an IC50 of 5.6 μM for reducing input resistance of the membrane potential. The Ki of CGS 21680 adenosine (A2A) subtype receptor is 27 nM. CGS 21680 has less affinity for A1 and A3 adenosine receptors than A2A- and A2B subtype. CGS 21680 starting at the onset of arthritis (Day 25) improved the clinical signs at Days 26-35 and ameliorated histological states in the joint and paw. The degree of oxidative and nitrosative damage was markedly decreased in CGS 21680-treated mice as exhibited by increased contents of malondialdehyde, formation of nitrotyrosine, and activation of poly (ADP-ribose) polymerase. Plasma levels of proinflammatory cytokines including tumor necrosis factor, interleukin 1ß (IL-1ß) and IL-6 were also decreased by CGS 21680. CGS 21680 also reduced the expression of inducible nitric oxide synthase and cyclooxygenase^-2.

>98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

CGS-21680;CGS21680

DMSO ：>19.3mg/mL